On December 5, Shanghai Aolu Biomedical Technology Co., Ltd. announced that it had successfully completed Series A financing of 100 million US dollars in June 2025. This round of financing was jointly funded by Temasek's wholly-owned subsidiary Danming Capital, Eli Lilly Asia Fund, Pfizer Ventures, and Sirona Capital.

On December 5, Shanghai Aolu Biomedical Technology Co., Ltd. announced that it had successfully completed Series A financing of 100 million US dollars in June 2025. This round of financing was jointly funded by Temasek's wholly-owned subsidiary Danming Capital, Eli Lilly Asia Fund, Pfizer Ventures, and Sirona Capital.